Ann: Patent to 2034 granted in Europe for Neuren's NNZ-2591, page-20

today's session confirms that the title is absolutely controlled and manipulated and facts and figures prove it; in the face of positive news, the market imposes a markedly negative start and then recovers the values during the session, closing the game almost surgically, recording a perfect balance between purchases and sales. this is full and complete management of the title. from my point of view, this apparently inconsistent behavior follows more and more the hypothesis that there are ongoing confidential negotiations for the acquisition of the company; in this scenario, the price per share is the subject of the negotiation so it must not take value and impetus for any reason or news.in fact, however, we register an increasingly important intellectual property with a project of great ambition widely supported by the good that will come from the study being officially carried out by Acadia.I conclude by saying that for much less than what Neuren is now, every day small-scale biotech acquisitions are formalized with very substantial rewards. it's really hard to imagine that Treagus has no important demands in hand.I expect that the market will, by the end of the year, partially or completely discount what it wants to hide today.